Iyad Hamarneh, MD
Medical Oncology · Prescott, AZNPI 1427268259
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Gilead at 52.2% of the total. Reporting peaked in 2022 at $6,059 and has fallen 77.7% since, to $1,354 in 2025.
Across 302 payments — averaging $58.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- AstraZeneca$3K
- Pfizer$650
- Seagen Inc.$390
- Sanofi$355
- E.r. Squibb & Sons, L.L.C.$338
- plus $4K from 45 others
Across 300 payments — averaging $2792.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$481K
- AstraZeneca$162K
- Eli Lilly$158K
- Genentech, Inc.$31K
- Pfizer$6K
What the payments were for
- Consulting fees$8,58348%
- Travel & lodging$2,75116%
- Food & beverage$5,67732%
- Education$7334%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,744 in reported general payments places this provider in the 65th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 47 | $1,099,589 |
| Lenalidomide | 83 | $1,081,499 |
| XtandiEnzalutamide | 60 | $837,662 |
| JakafiRuxolitinib Phosphate | 46 | $605,770 |
| ImbruvicaIbrutinib | 27 | $418,031 |
| VerzenioAbemaciclib | 27 | $407,785 |
| KisqaliRibociclib Succinate | 24 | $404,098 |
| BrukinsaZanubrutinib | 20 | $305,544 |
| VenclextaVenetoclax | 35 | $273,818 |
| CalquenceAcalabrutinib Maleate | 19 | $271,219 |
| Abiraterone Acetate | 95 | $240,433 |
| TagrissoOsimertinib Mesylate | 14 | $239,347 |
| EliquisApixaban | 128 | $122,563 |
| XareltoRivaroxaban | 24 | $15,463 |
| Enoxaparin Sodium | 21 | $14,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $338 | $1,099,58947 claims |
| Astellas Pharma US IncXtandi | $81 | $837,66260 claims |
| Incyte CorporationJakafi | $84 | $605,77046 claims |
| AstraZenecaCalquence, Tagrisso | $2,798 | $510,56633 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $21 | $418,03127 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $55 | $408,00578 claims |
| NovartisKisqali | $192 | $404,09824 claims |
| Beigene USA, Inc.Brukinsa | $20 | $305,54420 claims |
| AbbVieVenclexta | $224 | $273,81835 claims |
| PfizerEliquis | $650 | $122,563128 claims |
| Johnson & JohnsonXarelto | $312 | $15,46324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 59 medical oncology providers in Arizona.
Other medical oncology in Prescott
- Allan Espinosa MorazanPrescott$5K
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Nazish AhmadGlendale$205K
- Daniel von HoffScottsdale$165K
- David KahnSurprise$47K
- Michael BookmanTucson$46K
- James EwingGlendale$42K
- Waqas ArslanPhoenix$39K
- Amber FlahertyPhoenix$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.